SCHEMBL6940338

SCHEMBL6940338

CC(C(=O)Nc1ccc(-n2cnc3c2CCCC3)c(C(F)(F)F)c1)c1cc(C(=N)N)ccc1O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F10 P00742 11/20 0.39
F9 P00740 6/20 0.39
F2 P00734 8/20 0.36
F7 P08709 2/20 0.36
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PRSS1 P07477 2/20 0.33
PRSS2 P07478 2/20 0.33
PRSS3 P35030 2/20 0.33
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
ANO1 Q5XXA6 1/20 0.32
CYP2C9 P11712 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7570036 0.99 F10 (0.38) F10F9F2F7TP53
SCHEMBL7560368 0.89 F10 (0.40) F10F9F2THRBPRSS1
SCHEMBL2990398 0.84 F7 (0.35) F2F7CYP2C9TAAR1
Hydrochloric Acid SCHEMBL6937642 0.84 F7 (0.35) F2F7CYP2C9TAAR1
SCHEMBL6942560 0.83 F10 (0.37) F10F2F7MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL6942076 0.82 F7 (0.35) F2F7CYP2C9TAAR1
Hydrochloric Acid SCHEMBL7562752 0.82 F10 (0.37) F10F2F7MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL7566967 0.76 F10 (0.36) F10F7MAPTPRSS1PRSS2
SCHEMBL2995346 0.76 F10 (0.44) F10F9F2F7SMN1; SMN2
Hydrochloric Acid SCHEMBL7524480 0.75 F10 (0.43) F10F9F2F7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370540-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-12-17 EP claimed
US-20020183519-A1 Antithrombotic carboxylic acid amides BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-12-05 US claimed
WO-2002072558-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-19 WO claimed
EP-1370540-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-12-17 EP disclosed
US-20020183519-A1 Antithrombotic carboxylic acid amides BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-12-05 US disclosed
WO-2002072558-A1 ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183519-A1 Antithrombotic carboxylic acid amides SERPINC1, TFPI, F2 F10 33/4885F9 10/4885F2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.